Dimerix Obtains US Patent for DMX-652 Extending Protection Through 2043, Advancing Acute Kidney Injury Clinical Trials

DMX-652 Patent Grant Enhances Dimerix’s Intellectual Property Portfolio Through Mid-2043

The USPTO has awarded a core patent for Dimerix’s DMX-652 compound titled "N-cyanopyrrolidines with activity as USP30 inhibitors" under patent number US 12,679,833. This patent covers composition of matter claims for the drug candidate, extending protection until 11 April 2043. This milestone solidifies Dimerix’s comprehensive intellectual property rights for DMX-652 across the US market, enhancing the asset’s long-term commercial potential by securing extended exclusivity for future approval and commercialization.

The patent term adjustment of 677 days granted by the USPTO extends the original expiration date from 2041 by almost two years, strengthening Dimerix’s defense against generic competition. Additionally, the company has filed a divisional patent application to pursue further claims that may cover specific formulations, uses, or manufacturing processes related to DMX-652, potentially broadening its intellectual property protection.

DMX-652’s Mechanism and Clinical Development Plan for Acute Kidney Injury

DMX-652 selectively inhibits USP30, a mitochondrial enzyme regulating the removal of damaged mitochondria. By blocking USP30, DMX-652 enhances mitochondrial quality control in injured kidney cells via mitophagy, a process removing and replacing damaged mitochondria. Formulated as an oral once-daily capsule, it offers convenient administration and may improve patient adherence. This mechanism is particularly relevant for acute kidney injury caused by ischemia, toxins, or sepsis-related damage, where mitochondrial dysfunction is a key factor.

The Phase 2 trial protocol for DMX-652 has FDA approval under an existing open Investigational New Drug application, allowing streamlined regulatory progress without the need for a new IND submission. Dimerix has pharmaceutical-grade drug product manufactured under current good manufacturing practice (GMP) standards, ready to support Phase 2 initiation. The trial will assess DMX-652’s ability to prevent kidney injury and maintain renal function in patients with acute kidney injury related to cardiac surgery.

Acute Kidney Injury Presents Significant Market Opportunity Without Approved Therapies

Acute kidney injury is a common and serious condition occurring especially after cardiac surgery and during sepsis, characterized by rapid kidney function decline and high morbidity and mortality. Approximately 260,000 patients annually in major markets including the US, Germany, France, Italy, Spain, and the UK are affected, making it a potential orphan drug indication. Currently, no approved therapies exist specifically for acute kidney injury, leaving a major unmet medical need.

Management today relies on supportive care, as no treatments address the underlying kidney injury mechanisms. Acute kidney injury increases risks of chronic kidney disease and long-term complications, impacting patient quality of life and healthcare systems. Notably, about 25% of patients undergoing on-pump cardiac surgery develop acute kidney injury, highlighting a critical opportunity for DMX-652 to provide preventive or therapeutic benefits.

Comprehensive DMX-652 Acquisition Includes Development and Manufacturing Assets

Dimerix’s acquisition of DMX-652 encompasses the chemical compound, intellectual property rights, and essential development and manufacturing assets to advance commercialization. The composition of matter patent protection transfers ownership to Dimerix across key jurisdictions. The acquisition also includes an open FDA Investigational New Drug application permitting clinical trials under FDA oversight, with an approved Phase 2 protocol ready to proceed, eliminating regulatory delays.

Additionally, Dimerix obtained pharmaceutical-grade drug product manufactured under GMP standards along with all manufacturing methodologies required for Phase 2 trials. This comprehensive package enables swift trial initiation without further manufacturing development or regulatory hurdles, reducing technical and commercial risks associated with scaling production if clinical success is achieved.

Dimerix’s Pipeline Also Features Phase 3 Program for Focal Segmental Glomerulosclerosis

Beyond DMX-652, Dimerix is advancing DMX-200, its lead program currently in Phase 3 for focal segmental glomerulosclerosis (FSGS), a severe rare kidney disease marked by progressive scarring of the kidney’s filtering units. FSGS leads to proteinuria, kidney function decline, and often end-stage renal disease requiring dialysis or transplant. In the US, over 40,000 adults and children are estimated to live with FSGS, representing a significant unmet medical need.

DMX-200 is a chemokine receptor antagonist targeting CCR2, involved in monocyte and macrophage activation contributing to glomerular injury in FSGS. It is administered alongside angiotensin II type I receptor blockers, the standard care for hypertension and kidney disease. DMX-200 holds granted patents in multiple territories until 2032, with additional applications potentially extending protection to 2042. The drug has received Orphan Drug Designation in the US, Europe, UK, and Japan, providing regulatory incentives and exclusivity for rare disease therapies.

Unmet Needs in FSGS Highlight Long-Term Commercial Potential for DMX-200

FSGS currently lacks specifically approved therapies in the US, with treatment relying on non-specific immunosuppressants and supportive care. The disease’s progressive nature means patients with resistant FSGS may reach end-stage renal disease within five years, underscoring the urgent need for disease-modifying treatments. Recurrence after kidney transplantation occurs in up to 60% of cases, suggesting systemic therapies like DMX-200 targeting underlying mechanisms may offer superior long-term outcomes.

DMX-200’s targeting of the CCR2 pathway aligns with the inflammatory processes driving FSGS progression, addressing a key disease mechanism. The combination of a defined patient population, orphan drug status, and a mechanism-based approach presents a compelling clinical and commercial opportunity as the drug advances through Phase 3 development.

Global Commercial Strategy Supported by Five International Partnerships

Dimerix is expanding its kidney disease treatment pipeline through five commercial partnerships worldwide, supporting development and future market access for DMX-200, DMX-652, and other candidates. These partnerships span multiple regions and indications, enabling global distribution and commercialization. This strategy mitigates development costs and risks by leveraging partners’ market access expertise, allowing Dimerix to focus on clinical development and regulatory approvals.

Early establishment of commercial relationships allows integration of partner insights on market needs, regulatory pathways, and commercialization strategies, potentially accelerating patient access. The presence of established partners also strengthens Dimerix’s negotiating position with regulators and potential acquirers by demonstrating market demand and industry commitment.

Divisional Patent Application Seeks Broader Intellectual Property Protection for DMX-652

In addition to the core patent, Dimerix has filed a divisional patent application with the USPTO to pursue additional claims for DMX-652. Divisional applications enable protection of different inventive aspects disclosed in the original application but not included in the granted patent, such as alternative formulations, specific uses, dosing regimens, patient populations, or manufacturing methods.

This approach can establish supplementary patent exclusivity layers complementing the core composition of matter patent, providing protection even against competitors developing chemically distinct but pharmacologically similar compounds. Filing divisional patents is a standard industry practice to maximize intellectual property value and extend market exclusivity, underscoring Dimerix’s commitment to building a robust patent estate around DMX-652.

Regulatory Pathway and Upcoming Clinical Milestones for DMX-652

Dimerix is set to commence Phase 2 clinical trials of DMX-652 for acute kidney injury associated with cardiac surgery, marking a key development milestone. FDA approval of the Phase 2 protocol under the existing open IND eliminates regulatory delays, enabling prompt patient recruitment and study start. The trial aims to demonstrate DMX-652’s efficacy in preventing kidney injury and preserving renal function, supporting potential progression to Phase 3.

Beyond cardiac surgery-related acute kidney injury, DMX-652 may expand into other indications involving mitochondrial dysfunction and impaired mitophagy, such as sepsis-induced or toxin-related kidney injury. Its oral once-daily formulation and mechanism targeting mitochondrial quality control suggest applicability across multiple kidney and potentially non-renal diseases involving mitochondrial impairment. Positive Phase 2 results would provide a foundation for broader development programs in these areas.